SGLT2 inhibitors have recently offered hope, with the DELIVER and EMPEROR-Preserved trials demonstrating reductions in composite endpoints of worsening heart failure or cardiovascular death in patients with LVEF >40% [11,12]. The gene discussed is SLC5A2; the disease is heart failure.